NAPSR News: New Report from Thomson Reuters Reveals Promising Outlook for Pharmaceutical Industry

According to Thomson Reuters, the pharmaceutical industry’s sales will amount to $1 Trillion in 2014.
By:
 
WASHINGTON - Sept. 9, 2014 - PRLog -- The Intellectual Property and Science business of Thomson Reuters (http://ip-science.thomsonreuters.com/) has released its annual report of pharmaceutical industry trends in its 2014 Pharmaceutical R&D CMR Factbook (http://cmr.thomsonreuters.com/). According to the report, the biopharmaceutical industry has retained positive trends encompassing high pharmaceutical sales, an increase in New Molecular Entities (NMEs), and successful therapies completing late stage clinical trials.

The report revealed, global pharmaceutical sales is at an all-time high of approximately $980 billion in 2013 and are expected to increase to $1 trillion this year. In 2013, the NMEs (New Molecular Entities) or novel drugs launched represent the third highest number in the last decade. The industry has specifically been responsive to the research and development of therapies to treat rare diseases and areas of unmet need. Many of the drugs launched have been specifically indicated to treat cancer, pulmonary arterial hypertension and HIV. Majority of the anti-cancer therapies have received orphan drug status from the FDA. The report goes on to discuss a trend in success rates for dugs across late stage clinical studies, improving the industry’s ability to "fail fast, fail cheaply’’ thus producing a high success rate for advanced drug candidates. "Pharmaceutical R&D is a difficult and expensive process in an industry with high expectations," said Jon Brett-Harris, managing director of Thomson Reuters Life Sciences.  "With much of the recent conversation focused on the hurdles in the pharma space, it is reassuring to see positive developments and an encouraging future landscape."

The CMR Factbook was compiled by the Thomson Reuters Life Sciences Professional Services team and focuses on covering key trends in the pharmaceutical sector.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.

Contact
NAPSRx
***@napsronline.org
1-800-284-1060
End
Source: » Follow
Email:***@napsronline.org Email Verified
Tags:Napsr, Napsrx, Naprx, Cnpr Certification, Pharmaceutical Sales
Industry:Biotech, Health
Location:Washington - District of Columbia - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
NAPSRx PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share